

CURRICULUM VITAE & PUBLICATION LIST

Markus Mitterhauser, PhD, MSc, Professor



Personal Information

Nationality: Austrian

Date & Place of Birth: 19. Mai 1970 in Vienna

Email: markus.mitterhauser@meduniwien.ac.at

Business address: Hospital Pharmacy and Dept. Nuclear Medicine
General Hospital of Vienna Währinger Gürtel 18-20 A-1090 Vienna

Tel: +4314040055340

Fax: +4314040015590

Webpage: www.applied-diagnostics.at

Current Positions

- * Director: Ludwig Boltzmann Institute Applied Diagnostics
- * Head: Radiopharmacy and experimental Nuclear Medicine, Hospital Pharmacy and Dept. Nuclear Medicine
- * Head: Radiopharmaceutical Sciences & Functional Imaging, University of Applied Sciences, Wiener Neustadt
- * Speaker: Preclinical Imaging Node of the Medical Imaging Cluster at the Medical University of Vienna
- * Head: Radiopharmacy working group of the OGN
- * Austrian delegate to the radiopharmacy working group of the DGN
- * Austrian delegate to the radiopharmacy committee of the EANM

Education

Currently Visiting Professor for Radiopharmacy and Experimental Nuclear Medicine at the University of Vienna

November 2006: Habilitation for Radiopharmacy at the Medical University of Vienna

November 2006: Approval as Hospital Pharmacist (aHPh)

November 2003: PhD degree at the institute for pharmaceutical technology and biopharmaceutics

March 1999-Oct. 2000: Postgraduate diploma course Radiopharmacy/Radiopharmaceutical chemistry at ETH Zürich

Feb 1997-Sept. 1998: Employed as a pharmacist at the public pharmacy "Joh. Nepomuk" (Vienna)
 Approbation as pharmacist and apothecary concession (Mar. 1998)

Oct. 1996: Masters Degree in Pharmaceutical Sciences

1980-1988: „Humanistisches Gymnasium Kollegium Kalksburg“, Vienna

1976-1980: Primary school in Vienna

Internships and professional experience

March-Oct.1993 Diploma thesis at the Karolinska Institutet/Stockholm, Sweden and Turku PET-Center/Turku, Finland. Title: "On the Synthesis of C-11 Norepinephrine and C-11 Metaraminol for PET"

June-Aug.1994 and June-Aug. Research visits at the Chinese University of Hong Kong, 1995 CUHK; Hong Kong. Aim: Pharmacological investigations on 11-β-hydroxylase-Inhibitors in the adrenal cortex

Juni-July 1996 Research visit at the SHFJ in Orsay near Paris, France Aim: Radiolabelling of the in Hong Kong evaluated 11-β-hydroxylase-Inhibitors with Br-76 for PET.

Funding

Principal Investigator:

June 2005	Austrian National Bank project number #11439: "[¹⁸ F]FE@CIT"	€ 76.000
October 2006	FWF "Austrian Science Fund", project #19383: "[¹⁸ F]FE@SUPPLY"	€ 301.000
June 2008	FWF "Austrian Science Fund", project #20977: "[¹¹ C]SNAP-7941 and [¹⁸ F]FE@SNAP"	€ 309.500
December 2009	Austrian National Bank project number #13675: "[¹¹ C]DASB and ADHS"	€ 76.000
December 2011	CCC RCG011: „Simultaneous PET-MRI of the prostate for improved diagnosis and advanced radiotherapy treatment“	€ 99.500
March 2014	FWF "Austrian Science Fund", project #19383: "[¹⁸ F]FE@SUPPLY"	€ 354.000
December 2015	LBG Ludwig Boltzmann Institute for Applied Diagnostics	€ 5.560.000

Awards

March 1994-Oct 1994	Erasmus scholarship at the Karolinska Hospital, Dept. Psychiatry	€3400
July 1996-August 1996	EC-short term scientific mission support at the Service Hospitalier Frederic Joliot; Le Guichet, France	€1500
January 2004	THP award for the publication: In vivo and in vitro evaluation of [¹⁸ F]FETO with respect to the adrenocortical and GABAergic system in rats.	€1500

Memberships

Editorial Board for The Open Nuclear Medicine Journal

Austrian Society of Nuclear Medicine (OGN, head of radiopharmaceutical working group)

Radiopharmacy Group of the German Society of Nuclear Medicine

European Association of Nuclear Medicine (EANM), National Delegate

Austrian Chamber of Pharmacists (Österreichische Apothekerkammer)

VIRRAD Group (virtual radiopharmacy project of the EC)Association)

Personal Interests

Triathlon, Skiing, Music (piano), Hiking

Scientific publications (2012-2017)

Currently 151 Peer reviewed research articles; H-index 24, Scopus EXPORT DATE:23.4.2017

1. Vranka C, Nics L, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. LogP, a yesterday's value? Nucl Med Biol. 2017 21;50:1-10.
2. Zeilinger M, Pichler F, Nics L, Wadsak W, Spreitzer H, Hacker M, Mitterhauser M. New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. EJNMMI Res. 2017; 7(1):22.
3. Li X, Heber D, Cal-Gonzales J, Karanikas G, Mayerhoefer ME, Rasul S, Beitzke D, Zhang X, Agis H, Mitterhauser M, Wadsak W, Beyer T, Loewe C, Hacker M. Association between osteogenesis and inflammation during the progression of calcified plaque as evaluated by combined 18F-NaF and 18F-FDG PET/CT. J Nucl Med. 2017 in press.
4. James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A, Gryglewski G, Hienert M, Spies M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. Front Hum Neurosci. 2017;11:48.
5. Gryglewski G, Rischka L, Philippe C, Hahn A, James GM, Klebermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, Berroterán-Infante N, Nics L, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. Neuroimage. 2017;149:23-32.
6. Komorowski A, James GM, Philippe C, Gryglewski G, Bauer A, Hienert M, Spies M, Kautzky A, Vanicek T, Hahn A, Traub-Weidinger T, Winkler D, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. Cereb Cortex. 2017;27(1):117-130.
7. Vanicek T, Kutzelnigg A, Philippe C, Sigurdardottir HL, James GM, Hahn A, Kranz GS, Höflich A, Kautzky A, Traub-Weidinger T, Hacker M, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. Hum Brain Mapp. 2017;38(2):792-802.
8. El-Rabadi K, Weber M, Mayerhofer M, Nakuz T, Scherer T, Mitterhauser M, Dudczak R, Hacker M, Karanikas G. Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma. Anticancer Res. 2016;36(8):4187-93.
9. Pöppel TD, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzl A, Krause BJ, Krause T, Mitterhauser M, Scheidhauer K, Schenck M, Sonnenschein W, Gabriel M. [Therapy of bone metastases with radium-223. German guidelines]. Nuklearmedizin. 2016;55(5):177-86.
10. Hahn A, Gryglewski G, Nics L, Hienert M, Rischka L, Vranka C, Sigurdardottir H, Vanicek T, James GM, Seiger R, Kautzky A, Silberbauer L, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG. J Nucl Med. 2016;57(12):1933-40.

11. Steiner E, Kazianka L, Breuer R, Hacker M, Wadsak W, Mitterhauser M, Stimpfl T, Reiter B, Karanikas G, Miholic J. Postprandial pancreatic [11C]methionine uptake after pancreaticoduodenectomy mirrors basal beta cell function and insulin release. *Eur J Nucl Med Mol Imaging*. 2017;44(3):509-516.
12. Rami-Mark C, Berroterán-Infante N, Philippe C, Foltin S, Vranka C, Hoepfing A, Lanzenberger R, Hacker M, Mitterhauser M, Wadsak W. Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI(2015) *EJNMMI Research*, 5, in press.
13. Neudorfer C, Shanab K, Holzer W, Rami-Mark C, Mitterhauser M, Wadsak W, Spreitzer H. 2-fluoro-N-methyl-N-(((3s*,4s*)-4-(2-methylphenoxy)-3,4-dihydro-1H-isochromen-3-yl)methyl)ethanamine (2015) *MolBank*, 2015 (2), in press.
14. Neudorfer C, Shanab K, Holzer W, Rami-Mark C, Mitterhauser M, Wadsak W, Spreitzer H. 2-Fluoro-N-methyl-N-(((3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1H-isochromen-3-yl)methyl)ethanamine (2015) *MolBank*, 2015 in press.
15. Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding (2015) *NeuroImage*, 111, 505-512.
16. Haeusler D, Grassinger L, Fuchshuber F, Hörleinsberger WJ, Höftberger R, Leisser I, Girschele F, Shanab K, Spreitzer H, Gerdenitsch W, Hacker M, Wadsak W, Mitterhauser M. Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor (2015) *European Journal of Nuclear Medicine and Molecular Imaging*, in press.
17. Philippe C, Zeilinger M, Mitterhauser M, Dumanic M, Lanzenberger R, Hacker M, Wadsak W. Parameter evaluation and fully-automated radiosynthesis of [11C]harmine for imaging of MAO-A for clinical trials (2015) *Applied Radiation and Isotopes*, 97, 182-7.
18. Neudorfer C, Seddik A, Shanab K, Jurik A, Rami-Mark C, Holzer W, Ecker G, Mitterhauser M, Wadsak W, Spreitzer H. Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter (2015) *Molecules*, 20, 1712-30.
19. Haeusler D, Kuntner C, Nics L, Savli M, Zeilinger M, Wanek T, Karagiannis P, Lanzenberger RR, Langer O, Shanab K, Spreitzer H, Wadsak W, Hacker M, Mitterhauser M. [18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents(2015) *European Journal of Nuclear Medicine and Molecular Imaging*, 42,741-9.
20. Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People (2014) *Biological Psychiatry*, in press.
21. Neudorfer C, Shanab K, Jurik A, Schreiber V, Neudorfer C, Vranka C, Schirmer E, Holzer W, Ecker G, Mitterhauser M, Wadsak W, Spreitzer H. Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease (2014) *Bioorganic and Medicinal Chemistry Letters*, . Article in Press.
22. Philippe C, Haeusler D, Fuchshuber F, Spreitzer H, Viernstein H, Hacker M, Wadsak W, Mitterhauser M. Comparative autoradiographic in vitro investigation of melanin concentrating hormone receptor 1 ligands in the central nervous system. (2014) *European Journal of Pharmacology*, 735, 177-183.
23. Mitterhauser M, Wadsak W. Imaging biomarkers or biomarker imaging? (2014) *Pharmaceuticals*, 7 (7), 765-778.
24. Baldinger P, Kranz GS, Haeusler D, Savli M, Spies M, Philippe C, Hahn A, Höflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET (2014) *NeuroImage*, 88, 252-262.
25. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, Boucher Y, Trebicka J, Trauner M, Angermayr B, Fuhrmann V, Reiberger T, Peck-Radosavljevic M. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats (2014) *Journal of Hepatology*, 60, 1135-1142.

26. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Hoeflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R. Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo (2014) *Brain Structure and Function*, 219, 171-183.
27. Stein P, Baldinger P, Kaufmann U, Christina R-M, Hahn A, Höflich A, Kranz GS, Savli M, Wadsak W, Mitterhauser M, Winkler D, Kasper S, Lanzenberger R. Relation of progesterone and DHEAS serum levels to 5-HT_{1A} receptor binding potential in pre- and postmenopausal women (2014) *Psychoneuroendocrinology*, 46, 52-63.
28. Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R, Kasper S. Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-¹¹C]WAY-100635 (2014) *Psychoneuroendocrinology*, 45, 1-10.
29. Magnaldi S, Mayerhoefer ME, Khameneh A, Schuetz M, Javor D, Mitterhauser M, Dudczak R, Hacker M, Karanikas G. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas. (2014) *Anticancer research*, 34, 791-795.
30. Hahn A, Haeusler D, Kraus C, Höflich AS, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression (2014) *Human Brain Mapping*, 35 (8), 3857-3866.
31. Shanab K, Neudorfer C, Holzer W, Mitterhauser M, Wadsak W, Spreitzer H. A One-Step microwave-assisted synthetic method for an o/s-chemoselective route to derivatives of the first adenosine a₃ pet radiotracer (2014) *Molecules*, 19, 4076-4082.
32. Baldinger P, Hahn A, Mitterhauser M, Kranz GS, Friedl M, Wadsak W, Kraus C, Ungersböck J, Hartmann A, Giegling I, Rujescu D, Kasper S, Lanzenberger R. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET (2013) *Brain Structure and Function*, Article in Press.
33. Rami-Mark C, Bornatowicz B, Fink C, Otter P, Ungersboeck J, Vraka C, Haeusler D, Nics L, Spreitzer H, Hacker M, Mitterhauser M, Wadsak W. Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [¹¹C]IPCIT and [¹⁸F]FE@IPCIT (2013) *Bioorganic and Medicinal Chemistry*, 21, 7562-9.
34. Rami-Mark C, Ungersboeck J, Haeusler D, Nics L, Philippe C, Mitterhauser M, Willeit M, Lanzenberger R, Karanikas G, Wadsak W. Reliable set-up for in-loop ¹¹C-carboxylations using Grignard reactions for the preparation of [carbonyl-¹¹C]WAY-100635 and [¹¹C]-(+)-PHNO (2013) *Applied Radiation and Isotopes*, 82, 75-80.
35. Rami-Mark C, Zhang M-R, Mitterhauser M, Lanzenberger R, Hacker M, Wadsak W. [¹⁸F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the norepinephrine transporter (2013) *Nuclear Medicine and Biology*, 40, 1049-54.
36. Schirmer E, Shanab K, Datterl B, Neudorfer C, Mitterhauser M, Wadsak W, Philippe C, Spreitzer H. Syntheses of precursors and reference compounds of the melanin-concentrating hormone receptor 1 (MCHR1) Tracers [¹¹C]SNAP-7941 and [¹⁸F]FE@SNAP for positron emission tomography (2013) *Molecules*, 18, 12119-43.
37. Philippe C, Nics L, Zeilinger M, Schirmer E, Spreitzer H, Karanikas G, Lanzenberger R, Viernstein H, Wadsak W, Mitterhauser M. Preparation and first preclinical evaluation of [¹⁸F]FE@SNAP: A potential PET tracer for the melanin-concentrating hormone receptor-1 (MCHR1) (2013) *Scientia Pharmaceutica*, 81, 625-39.
38. Philippe C, Nics L, Zeilinger M, Kuntner C, Wanek T, Mairinger S, Shanab K, Spreitzer H, Viernstein H, Wadsak W, Mitterhauser M. Preclinical in vitro & in vivo evaluation of [¹¹C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1 (2013) *Nuclear Medicine and Biology*, 40, 919-25.
39. Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jäger W, Haslacher H, Müller M, Langer O. Interaction of ¹¹C-tarividar and ¹¹C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier (2013) *Journal of Nuclear Medicine*, 54, 1181-7.

40. Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Raderer M, Trattnig S, Herneth A, Karanikas G. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen (2013) *European Radiology*, 23, 1978-85.
41. Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling (2013) *Liver International*, 33, 561-8.
42. Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W, Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R. Application of image-derived and venous input functions in major depression using [carbonyl-¹¹C]WAY-100635 (2013) *Nuclear Medicine and Biology*, 40,371-377.
43. Mark C, Bornatowicz B, Mitterhauser M, Hendl M, Nics L, Haeusler D, Lanzenberger R, Berger ML, Spreitzer H, Wadsak W. Development and automation of a novel NET-PET tracer: [¹¹C]Me@APPI (2013) *Nuclear Medicine and Biology*, 40,295-303.
44. Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET (2013) *Molecular Psychiatry*, Article in Press.
45. Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression (2013) *Molecular Psychiatry*, 18,1.
46. Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET (2013) *Molecular Psychiatry*, 18, 93-100.
47. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Hoeflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R. Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo (2012) *Brain Structure and Function*, pp. 1-13.
48. Nics L, Hahn A, Zeilinger M, Vraka C, Ungersboeck J, Haeusler D, Hartmann S, Wagner K-H, Lanzenberger R, Wadsak W, Mitterhauser M. Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-¹¹C]WAY-100635 in human plasma: An HPLC-assay which enables measurement of two patients in parallel (2012) *Applied Radiation and Isotopes*, 70, 2730-6.
49. Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, Spindelegger C, Ungersboeck J, Haeusler D, Mitterhauser M, Windischberger C, Wadsak W, Kasper S, Lanzenberger R. Serotonin-1A receptor binding is positively associated with gray matter volume - A multimodal neuroimaging study combining PET and structural MRI (2012) *NeuroImage*, 63, 1091-8.
50. Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, Mitterhauser M, Spindelegger C, Philippe C, Fink M, Wadsak W, Karanikas G, Kasper S. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas (2012) *NeuroImage*, 63, 874-81.
51. Ungersboeck J, Philippe C, Haeusler D, Mitterhauser M, Lanzenberger R, Dudczak R, Wadsak W. Optimization of [¹¹C]DASB-synthesis: Vessel-based and flow-through microreactor methods (2012) *Applied Radiation and Isotopes*, 70, 2615-20.
52. Savli M, Bauer A, Mitterhauser M, Ding Y-S, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani SA, Rattay F, Wadsak W, Kasper S, Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET (2012) *NeuroImage*, 63,447-59.

53. Philippe C, Schirmer E, Mitterhauser M, Shanab K, Lanzenberger R, Karanikas G, Spreitzer H, Viernstein H, Wadsak W. Radiosynthesis of [¹¹C]SNAP-7941-the first PET-tracer for the melanin concentrating hormone receptor 1 (MCHR1) (2012) *Applied Radiation and Isotopes*, 70,2287-94.
 54. Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Nics L, Zeilinger M, Shanab K, Lanzenberger R, Karanikas G, Spreitzer H, Viernstein H, Mitterhauser M, Wadsak W. FE@SNAP - A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): Microfluidic and vessel-based approaches (2012) *Bioorganic and Medicinal Chemistry*,20,5936-40.
 55. Ungersboeck J, Richter S, Collier L, Mitterhauser M, Karanikas G, Lanzenberger R, Dudczak R, Wadsak W. Radiolabeling of [¹⁸F]altanserin - a microfluidic approach (2012) *Nuclear Medicine and Biology*, 39,1087-92.
 56. Spindelegger C, Stein P, Wadsak W, Fink M, Mitterhauser M, Moser U, Savli M, Mien L-K, Akimova E, Hahn A, Willeit M, Kletter K, Kasper S, Lanzenberger R. Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain (2012) *World Journal of Biological Psychiatry*,13,413-22.
 57. Hahn A, Nics L, Baldinger P, Ungersböck J, Dolliner P, Frey R, Birkfellner W, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-¹¹C]WAY-100635 independent of arterial sampling (2012) *NeuroImage*,62,199-206.
 58. Baldinger P, Hahn A, Friedl M, Kranz GS, Ungersböck J, Höflich A, Mitterhauser M, Rujescu D, Wadsak W, Lanzenberger R, Kasper S. Influence of the HTR1A polymorphism rs878567 on the serotonin 1a binding potential in vivo [Einfluss des HTR1A-polymorphismus rs878567 auf das serotonin-1A- bindungspotenzial in vivo] (2012) *Journal für Neurologie, Neurochirurgie und Psychiatrie*, 13, 36-38.
 59. Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich AS, Losak J, Nics L, Philippe C, Kranz GS, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors (2012) *Proceedings of the National Academy of Sciences of the United States of America*, 109, 2619-24.
 60. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, Böhmendorfer M, Wadsak W, Mitterhauser M, Bankstahl JP, Löscher W, Koeppe M, Kuntner C, Müller M, Langer O. Pgp-mediated interaction between (R)- 11CVerapamil and tariquidar at the human blood-brain barrier: A comparison with rat data (2012) *Clinical Pharmacology and Therapeutics*,91,227-33.
-

10 most important Publications:

1. Mitterhauser M, Wadsak W. Imaging biomarkers or biomarker imaging? (2014) *Pharmaceuticals*, 7 (7), 765-778.
2. Philippe C, Nics L, Zeilinger M, Schirmer E, Spreitzer H, Karanikas G, Lanzenberger R, Viernstein H, Wadsak W, Mitterhauser M. Preparation and first preclinical evaluation of [¹⁸F]FE@SNAP: A potential PET tracer for the melanin-concentrating hormone receptor-1 (MCHR1) (2013) *Scientia Pharmaceutica*, 81, 625-39.
3. Philippe C, Nics L, Zeilinger M, Kuntner C, Wanek T, Mairinger S, Shanab K, Spreitzer H, Viernstein H, Wadsak W, Mitterhauser M. Preclinical in vitro & in vivo evaluation of [¹¹C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1 (2013) *Nuclear Medicine and Biology*, 40, 919-25.
4. Nics L, Hahn A, Zeilinger M, Vranka C, Ungersboeck J, Haeusler D, Hartmann S, Wagner K-H, Lanzenberger R, Wadsak W, Mitterhauser M. Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-¹¹C]WAY-100635 in human plasma: An HPLC-assay which enables measurement of two patients in parallel (2012) *Applied Radiation and Isotopes*, 70, 2730-6.
5. Mitterhauser M, Toegel S. Radiopharmaceutical considerations on bone seeker uptake: Should we learn from therapeutic targets of bisphosphonates? (2011) *Nuclear Medicine and Biology*, 38, 617-8.
6. Nics L, Haeusler D, Wadsak W, Wagner K-H, Dudczak R, Kletter K, Mitterhauser M. The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: There is no difference (2011) *Nuclear Medicine and Biology*, 38,13-7.
7. Haeusler D, Nics L, Mien L-K, Ungersboeck J, Lanzenberger RR, Shanab K, Sindelar KM, Viernstein H, Wagner K-H, Dudczak R, Kletter K, Wadsak W, Mitterhauser M. [¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 - metabolic considerations (2010) *Nuclear Medicine and Biology*, 37,421-6.
8. Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT (2010) *European Journal of Radiology*,73,461-9.
9. Mitterhauser M and Wadsak W. Evaluation of novel tropane analogues. (Letter to the editor) *Nucl Med Biol*. 2007; 34:591-2.
10. Mitterhauser M and Toegel S. An *in-vitro* Model for the Comparative Evaluation of Bone seeking Pharmaceuticals. *Altex* 2008;25:51-5.